Table 2.

TSOAC Pharmacokinetics

	Dabigatran	Rivaroxaban	Apixaban
Target	Factor IIa	Factor Xa	Factor Xa
Dosage Form	capsule	tablet	tablet
Bioavailability	6%	60-80%	50-85%
Time to Peak	1-2 hours	2-4 hours	1-3 hours
Metabolism	Conjugation; No CYP involvement	Oxidation via CYP3A4	Oxidation via CYP3A4
Renal Excretion	80%	33%	25%
Substrate of p- glycoprotein?	Yes	Yes	Yes
FDA approved dosing for stroke prevention in a- fib	150 mg twice daily for	20 mg by mouth once daily for patients CrCL > 50 ml/min	5 mg by mouth twice daily
	patients CrCL > 30 ml/min	15 mg by mouth once daily	2.5 mg by mouth twice daily for patients with 2 or more of the following: Age > 80, weight < 60 kg or Serum Cr > 1.5
	75 mg by mouth twice daily for CrCL 15–30 ml/min	for patients with CrCL 15-50 ml/min
FDA approved dosing for VTE prevention in hip	N/A	10 mg once daily for patients with CrCL > 30 ml/min	N/A
and knee
replacement
FDA approved	N/A	15 mg by mouth twice daily	N/A
dosing for {1) treatment of acute DVT or PE, or {2) long term prevention of		for 21 days, then 20 mg once daily for patients with CrCL > 30 ml/min
recurrent DVTfPE		20 mg once daily for patients with CrCL > 30 ml/min

CrCl = Creatinine Clearance, CYP = Cytochrome P450.